Ketoanalogue for Kidney Disease Market to be Worth US$ 409.6 Mn by the End 2031
Ketoanalogue for Kidney Disease Market to be Worth US$ 409.6 Mn by the End 2031
Stay updated with breaking news from Life Sciences Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ketoanalogue for Kidney Disease Market to be Worth US$ 409.6 Mn by the End 2031
Gene therapy clinical trial pipeline constitutes 250+ key companies continuously working towards developing 300+ gene therapies, analyzes DelveInsight LAS VEGAS, Nov. 2, 2022 /PRNewswire/
/PRNewswire/ -- DelveInsight's 'Gene Therapy Competitive Landscape – 2022' report provides comprehensive global coverage of available, marketed, and pipeline...
The Board of Directors of Glenmark Life Sciences Limited, at its meeting held today have approved the financial results of the company for the period ended September 30, 2022 - Q2FY23 and H1FY23.
NEW YORK, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, will